JAZZ (Jazz Pharmaceuticals) Accounts Payable: $100 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JAZZ Jazz Pharmaceuticals PLC JAZZ
73 GF Score
Price $257.64
GF Value $150.45
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Jazz Pharmaceuticals Accounts Payable?

Jazz Pharmaceuticals JAZZ +0.28% 73 Accounts Payable is $100 Mil as of Mar. 2026. GuruFocus rates JAZZ with a GF Score™ of 73/100 and a GF Value™ of $150.45 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Jazz Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2026 was $100 Mil.

Jazz Pharmaceuticals's quarterly Accounts Payable declined from Sep. 2025 ($152 Mil) to Dec. 2025 ($122 Mil) and declined from Dec. 2025 ($122 Mil) to Mar. 2026 ($100 Mil).

Jazz Pharmaceuticals's annual Accounts Payable declined from Dec. 2023 ($103 Mil) to Dec. 2024 ($78 Mil) but then increased from Dec. 2024 ($78 Mil) to Dec. 2025 ($122 Mil).

Jazz Pharmaceuticals Accounts Payable Related Terms

Jazz Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Jazz Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals Accounts Payable Chart

Jazz Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.30 90.76 102.75 77.87 122.06

Jazz Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 95.93 89.37 152.23 122.06 100.00
JAZZ
73GF Score
Jazz Pharmaceuticals PLC JAZZ
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jazz Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $100 Mil mean?
Jazz Pharmaceuticals (JAZZ) has a Accounts Payable of $100 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Jazz Pharmaceuticals and its competitors.
Is Jazz Pharmaceuticals' Accounts Payable too high?
Jazz Pharmaceuticals' current Accounts Payable is $100 Mil. Overall, Jazz Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jazz Pharmaceuticals' Accounts Payable compare to BBIO and ASND?
Jazz Pharmaceuticals' Accounts Payable of $100 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Jazz Pharmaceuticals and its competitors. Jazz Pharmaceuticals's current Accounts Payable is $100 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jazz Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jazz Pharmaceuticals (JAZZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $150.45, compared to a current price of $257.64 — trading 71.2% above its estimated fair value. The current Accounts Payable is $100 Mil. Jazz Pharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Jazz Pharmaceuticals (JAZZ), the current Accounts Payable is $100 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jazz Pharmaceuticals (JAZZ) Overvalued in 2026?

Based on GuruFocus' analysis, Jazz Pharmaceuticals stock appears to be overvalued. The current stock price of $257.64 is trading 71.2% above its estimated GF Value™ of $150.45. GuruFocus considers Jazz Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for JAZZ:

  • Accounts Payable: $100 Mil
  • GF Value™: $150.45 vs. price of $257.64 (71.2% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the JAZZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jazz Pharmaceuticals Business Description

Address Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
73GF Score

Get the complete analysis for JAZZ

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$257.64
Price
$150.45
GF Value